Persistent neutralising antibodies to interferon-beta and clinical outcomes in multiple sclerosis patients

被引：0
|
作者：
Costelloe, L. [1 ]
O'Rourke, K. [1 ]
Tubridy, N. [1 ]
Hutchinson, M. [1 ]
机构：
[1] St Vincents Univ Hosp, Dublin, Ireland
来源：
MULTIPLE SCLEROSIS | 2006年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [21] Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis
    Hyun, Jae-Won
    Kim, Gayoung
    Kim, Yeseul
    Kong, Byungsoo
    Joung, Aeran
    Park, Na Young
    Jang, Hyunmin
    Shin, Hyun-June
    Kim, Su-Hyun
    Ahn, Suk-Won
    Shin, Ha Young
    Huh, So-Young
    Kim, Woojun
    Park, Min Su
    Kim, Byung-Jo
    Kim, Byoung Joon
    Oh, Jeeyoung
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2018, 14 (02): : 186 - 190
  • [22] Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
    Sorensen, PS
    Ross, C
    Clemmesen, KM
    Bendtzen, K
    Frederiksen, JL
    Jensen, K
    Kristensen, O
    Petersen, T
    Rasmussen, S
    Ravnborg, M
    Stenager, E
    Koch-Henriksen, N
    LANCET, 2003, 362 (9391): : 1184 - 1191
  • [23] Immune tolerance induction with high-dose intravenous interferon-beta in multiple sclerosis patients with neutralising antibodies - a pilot study
    Hegen, H.
    Guger, M.
    Harrer, A.
    Hoelzl, M.
    Kraus, J.
    Schautzer, F.
    Schmidegg, S.
    Skrobal, A.
    Deisenhammer, F.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S424 - S425
  • [24] Measuring Neutralising Antibodies to interferon-beta: A neglected practice?
    McKee, Jon
    Spence, Robert
    Hughes, Stella
    Droogan, Aidan
    Gray, Orla
    Campbell, Jamie
    McDonnell, Gavin
    NEUROLOGY, 2021, 96 (15)
  • [25] Clinical efficacy and neutralising antibodies in multiple sclerosis patients treated with interferon-β
    D'hooghe, MB
    Nagels, G
    Van Remoortel, A
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S254 - S254
  • [26] The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis
    Koch-Henriksen, N.
    Sorensen, P. S.
    Bendtzen, K.
    Flachs, E. M.
    MULTIPLE SCLEROSIS, 2009, 15 (05): : 601 - 605
  • [27] Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients
    Kalluri, Sudhakar Reddy
    Grummel, Verena
    Hracsko, Zsuzsanna
    Pongratz, Viola
    Pernpeintner, Verena
    Gasperi, Christiane
    Buck, Dorothea
    Hemmer, Bernhard
    JOURNAL OF AUTOIMMUNITY, 2018, 88 : 83 - 90
  • [28] Neutralising antibodies to interferon beta in a population-based cohort of patients with multiple sclerosis
    Cossoy, M. B.
    Rush, C.
    Kremenchutzky, M.
    Bhan, V.
    MULTIPLE SCLEROSIS JOURNAL, 2007, 13 : S61 - S61
  • [29] Neutralising antibodies in patients with multiple sclerosis treated with interferon beta-1b
    Río, J
    Barberà, N
    Tintoré, M
    Brieva, L
    Montalbán, X
    MEDICINA CLINICA, 2000, 114 (05): : 169 - 170
  • [30] NEUTRALIZING ANTIBODIES AGAINST INTERFERON-BETA IN BULGARIAN ADOLESCENT MULTIPLE SCLEROSIS PATIENTS
    Ivanova, Sonya
    Skrobanska, Raliza
    Kolyovska, Vera
    Milanov, Ivan
    Dimitrova, Valentina
    Bojinova, Veneta
    COMPTES RENDUS DE L ACADEMIE BULGARE DES SCIENCES, 2018, 71 (09): : 1265 - 1271
12345